These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23274591)

  • 1. Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation.
    Janavičius R; Rudaitis V; Feng BJ; Ozolina S; Griškevičius L; Goldgar D; Tihomirova L
    Eur J Med Genet; 2013 Mar; 56(3):125-30. PubMed ID: 23274591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4154delA mutation carriers in the BRCA1 gene share a common ancestry.
    Ozolina S; Sinicka O; Jankevics E; Inashkina I; Lubinski J; Gorski B; Gronwald J; Nasedkina T; Fedorova O; Lyubchenko L; Tihomirova L
    Fam Cancer; 2009; 8(1):1-4. PubMed ID: 19067236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.
    Hamel N; Feng BJ; Foretova L; Stoppa-Lyonnet D; Narod SA; Imyanitov E; Sinilnikova O; Tihomirova L; Lubinski J; Gronwald J; Gorski B; Hansen Tv; Nielsen FC; Thomassen M; Yannoukakos D; Konstantopoulou I; Zajac V; Ciernikova S; Couch FJ; Greenwood CM; Goldgar DE; Foulkes WD
    Eur J Hum Genet; 2011 Mar; 19(3):300-6. PubMed ID: 21119707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
    Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
    Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
    Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
    Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals.
    Kaufman B; Laitman Y; Gronwald J; Lubinski J; Friedman E
    Genet Test Mol Biomarkers; 2009 Aug; 13(4):465-9. PubMed ID: 19594371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia.
    Tihomirova L; Vaivade I; Fokina O; Peculis R; Mandrika I; Sinicka O; Stengrevics A; Krilova A; Keire G; Petrevics J; Eglitis J; Timofejevs M; Leja M
    Adv Med Sci; 2014 Mar; 59(1):114-9. PubMed ID: 24797986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review.
    Loza P; Irmejs A; Daneberga Z; Miklasevics E; Berga-Svitina E; Subatniece S; Maksimenko J; Trofimovics G; Tauvena E; Ukleikins S; Gardovskis J
    Hered Cancer Clin Pract; 2021 Jan; 19(1):11. PubMed ID: 33468216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
    Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis.
    Marroni F; Cipollini G; Peissel B; D'Andrea E; Pensabene M; Radice P; Caligo MA; Presciuttini S; Bevilacqua G
    Ann Hum Genet; 2008 May; 72(Pt 3):310-8. PubMed ID: 18215206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
    Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
    Pertesi M; Konstantopoulou I; Yannoukakos D
    Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
    Rudkin TM; Hamel N; Galvez M; Hogervorst F; Gille JJ; Møller P; Apold J; Foulkes WD
    BMC Med Genet; 2006 Mar; 7():15. PubMed ID: 16509964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA haplotype map of river valley populations with hemochromatosis traced through five centuries in Central Sweden.
    Olsson KS; Ritter B; Hansson N; Chowdhury RR
    Eur J Haematol; 2008 Jul; 81(1):36-46. PubMed ID: 18363869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
    Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
    Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
    Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
    Genes Chromosomes Cancer; 2001 Jun; 31(2):107-16. PubMed ID: 11319798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
    Papi L; Putignano AL; Congregati C; Zanna I; Sera F; Morrone D; Falchetti M; Turco MR; Ottini L; Palli D; Genuardi M
    Breast Cancer Res Treat; 2009 Oct; 117(3):497-504. PubMed ID: 18821011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a few founder mutations.
    Moulard B; Genton P; Grid D; Jeanpierre M; Ouazzani R; Mrabet A; Morris M; LeGuern E; Dravet C; Mauguière F; Utermann B; Baldy-Moulinier M; Belaidi H; Bertran F; Biraben A; Ali Chérif A; Chkili T; Crespel A; Darcel F; Dulac O; Geny C; Humbert-Claude V; Kassiotis P; Buresi C; Malafosse A
    Hum Genet; 2002 Sep; 111(3):255-62. PubMed ID: 12215838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa.
    Richard P; Gaudon K; Haddad H; Ammar AB; Genin E; Bauché S; Paturneau-Jouas M; Müller JS; Lochmüller H; Grid D; Hamri A; Nouioua S; Tazir M; Mayer M; Desnuelle C; Barois A; Chabrol B; Pouget J; Koenig J; Gouider-Khouja N; Hentati F; Eymard B; Hantaï D
    Neurology; 2008 Dec; 71(24):1967-72. PubMed ID: 19064877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.